ArticleHaematologica2024

Minimal residual disease assessment in transplant-eligible patients with multiple myeloma: real-world applications of multiparametric flow cytometry-DURAClone (CAREMM-2104).

Ari Ahn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.